2025-10-14 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the provided data, formatted as requested with a brief English report followed by the key numbers and analysis.

## Eli Lilly & Co. (LLY) Stock Analysis

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **Key Numbers:**
    *   LLY Cumulative Return: 213.75%
    *   VOO Cumulative Return: 96.68%
    *   Absolute Spread: 120.5
    *   Relative Spread: 54.6

*   **Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period represented by the cumulative return data. The relative spread of 54.6 indicates that LLY's outperformance is positioned in the upper half of its historical range relative to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap(B) |
|------------|--------|--------|--------|--------|--------|
| 2015-2017  | 11.0%  | 76.1%  | -17.0% | -0.0   | 75.7   |
| 2016-2018  | 39.0%  | 68.9%  | 24.0%  | -0.0   | 103.7  |
| 2017-2019  | 41.0%  | 68.9%  | 19.0%  | 0.4    | 117.8  |
| 2018-2020  | 34.0%  | 79.8%  | 10.0%  | 0.4    | 151.4  |
| 2019-2021  | 53.0%  | 79.8%  | 7.0%   | 0.5    | 247.6  |
| 2020-2022  | 64.0%  | 79.8%  | 65.0%  | 0.4    | 328.0  |
| 2021-2023  | 125.0% | 78.9%  | 124.0% | 0.2    | 522.6  |
| 2022-2024  | 134.0% | 81.2%  | 113.0% | 0.2    | 692.1  |
| 2023-2025  | 105.0% | 83.5%  | 44.0%  | 0.2    | 734.6  |

*   **CAGR (Compound Annual Growth Rate):** The CAGR demonstrates a substantial growth trajectory for LLY, particularly in recent years (2021-2025).
*   **MDD (Maximum Drawdown):** The MDD figures indicate the potential downside risk, which is consistently high across the periods.
*   **Alpha:** A positive alpha indicates that the investment has outperformed its benchmark on a risk-adjusted basis. The high alpha values in recent years (2020-2024) suggest significant outperformance.
*   **Beta:** A beta close to 0 indicates that the stock has a low correlation with the market.
*   **Cap(B) (Market Capitalization in Billions):** The increasing market capitalization reflects the company's growth and investor confidence.

**2. Recent Stock Price Movement**

*   **Key Numbers:**
    *   Current Price: 819.40
    *   Previous Close: 833.49
    *   Change: -1.69%
    *   5-Day Moving Average: 835.37
    *   20-Day Moving Average: 785.84
    *   60-Day Moving Average: 749.66

*   **Analysis:** The current price is below both the 5-day and previous close, indicating a short-term downward trend.  The 5-day moving average is above the 20-day, which is above the 60-day.  The -1.69% change suggests a significant intraday drop, potentially triggering volatility concerns.

**3. Technical Indicators & Expected Return**

*   **Key Numbers:**
    *   MRI: 0.8 (Medium Investment Recommended)
    *   RSI: 68.99
    *   PPO: 0.52
    *   Relative Divergence Change (20-day): 1.8 (Positive - Short-term Increase)
    *   Expected Return: 113.0%

*   **Analysis:** The Market Risk Indicator (MRI) of 0.8 suggests a medium investment recommendation. The RSI of 68.99 indicates that the stock is approaching overbought territory.  The positive change in relative divergence suggests a short-term upward momentum.  The expected return of 113.0% is highly optimistic, indicating significant potential outperformance compared to the S&P 500 over the long term (2+ years).  The system's signal of "cash_0%_Buy 100% of cash" suggests a strong buy recommendation based on the algorithm.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   AZN Strikes Drug Pricing Deal
    *   New US biotech hubs
    *   Viking Therapeutics - Buy the Dip?
    *   Eli Lilly Omvoh - Long-Term Benefits
    *   Roche's Elecsys® pTau181 FDA-cleared
    *   Eli Lilly, WHO - Dementia Collaboration

*   **Analysis:** The news headlines present a mixed picture.  The AstraZeneca (AZN) pricing deal may create competitive pressures.  The news regarding Eli Lilly's Omvoh and the WHO collaboration is positive, highlighting progress in key therapeutic areas.

**4-2. Analyst Opinions**

*   **Key Numbers:**
    *   Consensus: Buy (1.79)
    *   Target Price: 891.00 (Average)

*   **Analysis:**  The analyst consensus is a "Buy" with an average target price of $891.00. This indicates that analysts generally expect the stock price to increase.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출        |
|--------------|------|-------------|
| 2025-08-07   | 6.3  | 15.56 B$   |
| 2025-05-01   | 3.07 | 12.73 B$   |
| 2024-10-30   | 1.08 | 11.44 B$   |
| 2024-08-08   | 3.29 | 11.30 B$   |
| 2025-08-07   | 3.29 | 11.30 B$   |

*   **Analysis:** The most recent EPS significantly exceeds previous reports, and the most recent revenue ($15.56B) is the highest in the provided dataset. This is a strong positive signal.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | $18.27B    | 30.98%   |
| 2025-03-31   | $15.76B    | 17.50%   |
| 2024-12-31   | $14.19B    | 31.07%   |
| 2024-09-30   | $14.24B    | 6.81%    |
| 2024-06-30   | $13.56B    | 21.88%   |

*   **Analysis:** Both revenue and profit margin have been consistently increasing, indicating strong financial performance. The ROE (Return on Equity) values show variability, but the recent value is relatively high.

**7. 종합 분석 (Overall Analysis)**

LLY demonstrates strong financial performance, outperforming the S&P 500. Recent earnings and financial data (revenue, profit margin) are highly positive. Analyst opinions are favorable ("Buy").

However, there are some cautionary points. The recent stock price dip and the "approaching overbought" RSI warrant caution. The high expected return is also ambitious. The high MDD values indicate the potential downside risk.

**In conclusion, based on the provided data, LLY appears to be a potentially attractive investment, but investors should be aware of the potential downside risks and monitor the stock's performance closely.**
